Peralta factual exhibit: FY2025 annual report; original: Novartis Annual Report 2025, physical

Reconstructed facts. Check publisher and locator in the report source index.

FY2025 sales USD 54532m versus FY2024 USD 50317m; FY2023 USD 45440m. [p174]

FY2025 IFRS operating income USD 17644m versus FY2024 USD 14544m. [p174]

FY2025 R&D expense USD 11200m; FY2024 USD 10022m. [p174]

FY2025 net income attributable USD 13984m; diluted EPS USD 7.15. [p174]

FY2025 cash from operations USD 19144m; FY2024 USD 17619m. [p178]

FY2025 PPE purchases USD 1548m and intangible purchases USD 2352m. [p178]

FY2025 company dividends USD 7818m and treasury purchases USD 9212m. [p178]

FY2025 total assets USD 110949m; common equity USD 46130m. [p176]

FY2025 financial debt USD 33537m and cash USD 11435m. [p176]

Prepared 2026-11-25 (Vancouver). USD millions unless otherwise stated.

Peralta factual exhibit: Q3 2026 report; original: Novartis 9M/Q3 interim, physical pages 3, 19

Reconstructed facts. Check publisher and locator in the report source index.

9M 2026 sales USD 42043m versus 9M 2025 USD 41196m. [p19]

9M 2026 IFRS operating income USD 10828m versus USD 14028m. [p19]

9M 2026 R&D expense USD 10737m versus USD 8037m. [p19]

9M 2026 cash from operations USD 15061m versus USD 16880m. [p25]

9M 2026 PPE purchases USD 1059m and intangible purchases USD 1248m. [p25]

9M 2026 dividends USD 9068m and treasury purchases USD 4772m. [p25]

9M 2026 acquisition cash USD 12813m plus concentration-test assets USD 2720m. [p25]

Sep 2026 net debt USD 37374m; common equity USD 37228m. [p52,p21]

Sep 2026 diluted quarterly shares 1905m; one ADR equals one share. [p18; issuer FAQ]

9M 2026 Kisqali USD 5032m; Kesimpta USD 4072m; Entresto USD 3651m. [p38]

9M 2026 Leqvio USD 1438m; established brands USD 10127m. [p38]

Q3 2026 Entresto sales USD 1165m, down 38% on generic competition. [p6]

Prepared 2026-11-25 (Vancouver). USD millions unless otherwise stated.

Peralta factual exhibit: Issuer announcements, share data and market observations, source URLs

Reconstructed facts. Check publisher and locator in the report source index.

Nov 19 outlook: 2026-2031 sales CAGR plus 5% constant currency. [issuer release]

Nov 19 outlook: core operating margin above 40% by 2029. [issuer release]

Nov 19 outlook: Leqvio, Kesimpta, Scemblix peak sales targets upgraded. [issuer release]

Nov 23 ORION-4 met primary MACE endpoint; full data planned H1 2027. [issuer]

Nov 25 NVS NYSE unadjusted close USD 155.29; source Stocknear historical table.

Nov 25 Bank of Canada FXUSDCAD daily average 1.4219 CAD per USD. [Valet]

Novartis NVS ADR listed NYSE in USD; ADR ratio one ordinary share. [issuer FAQ]

2026 ADR payment: 65% first; remainder only after successful reclaim. [issuer FAQ]

Dec 2025 outstanding ordinary shares 1908151679; 2024 1975089248. [issuer FAQ]

Dec 2025 registered holders about 184000; nominees hold 39.39% registered shares.

2025 Roche group sales CHF 61516m; core operating profit CHF 21833m. [Roche]

2025 Roche R&D core investments CHF 12243m; pharma sales CHF 47669m. [Roche]

2025 Merck sales USD 65011m; R&D expense USD 15800m. [Merck]

Prepared 2026-11-25 (Vancouver). USD millions unless otherwise stated.

Peralta factual exhibit: Annual statement rows; Novartis 2025 20-F, physical pp174/176/178

Reconstructed facts. Check publisher and locator in the report source index.

Annual sales 2023 45440; 2024 50317; 2025 54532 USD m. [p174]

Annual R&D 2023 11371; 2024 10022; 2025 11200 USD m. [p174]

Annual IFRS operating income 2023 9769; 2024 14544; 2025 17644 USD m. [p174]

Annual common net income 2023 14850; 2024 11941; 2025 13984 USD m. [p174]

Annual operating cash 2023 14458; 2024 17619; 2025 19144 USD m. [p178]

Annual PPE purchases 2023 1060; 2024 1366; 2025 1548 USD m. [p178]

Annual intangible purchases 2023 1693; 2024 2448; 2025 2352 USD m. [p178]

Annual dividends 2023 7255; 2024 7624; 2025 7818 USD m. [p178]

Annual treasury purchases 2023 8719; 2024 8331; 2025 9212 USD m. [p178]

Annual total assets 2024 102246; 2025 110949 USD m. [p176]

Annual cash 2024 11459; 2025 11435 USD m. [p176]

Annual financial debt 2024 29598; 2025 33537 USD m. [p176]

Annual common equity 2024 44046; 2025 46130 USD m. [p176]

Peralta factual exhibit: Interim statement rows; Novartis Q3 2026, physical pp19/21/25/52

Reconstructed facts. Check publisher and locator in the report source index.

9M sales 2025 41196; 2026 42043 USD m. [p19]

9M R&D 2025 8037; 2026 10737 USD m. [p19]

9M IFRS operating income 2025 14028; 2026 10828 USD m. [p19]

9M common net income 2025 11575; 2026 7622 USD m. [p19]

9M operating cash 2025 16880; 2026 15061 USD m. [p25]

9M PPE purchases 2025 939; 2026 1059 USD m. [p25]

9M intangible purchases 2025 1944; 2026 1248 USD m. [p25]

9M dividends 2025 7818; 2026 9068 USD m. [p25]

9M treasury purchases 2025 7732; 2026 4772 USD m. [p25]

9M acquisitions 2025 1757; 2026 15533 USD m. [p25]

Sep 2026 assets 117149; cash 8870; common equity 37228 USD m. [p21]

Sep 2026 financial debts plus derivatives 46349; leases 1961 USD m. [p21]

Sep 2026 issuer net debt 37374; Dec 2025 21947 USD m. [p52]

Prepared 2026-11-25 (Vancouver). USD millions unless otherwise stated.

Peralta factual exhibit: Ownership, peer and rate facts; original publisher locators in source

Reconstructed facts. Check publisher and locator in the report source index.

Dec 2025 BlackRock 139392071 shares, 7.3% outstanding. [20-F Item 7.A p140]

Dec 2025 UBS 139602467 shares, 7.3% outstanding. [20-F Item 7.A p140]

Dec 2025 184000 registered holders; 39.4% nominee/depositary. [20-F p140]

Roche 2025 sales CHF 61516m; 2024 CHF 60495m; core R&D CHF 12243m. [annual]

Merck 2025 sales USD 65011m; 2024 USD 64168m; R&D USD 15800m. [FY release]

Nov 25 US Treasury 10-year par yield 4.85%. [Treasury monthly table row]

Prepared 2026-11-25 (Vancouver). USD millions unless otherwise stated.

Peralta factual exhibit: additional financing and share-basis facts

Reconstructed facts. Check original publisher and physical locator in source index.

FY2023 deal cash 3561m; FY2024 4018m; FY2025 2916m USD. [20-F p178]

Q3 2026 del-desiran acquired IPR&D impairment USD 1900m. [Q3 p4]

Sep 2026 actual outstanding shares 1888623572; 2025 yearend 1908151679. [Q3 p52]

ADR cash distribution fee at most USD 0.05 per ADS. [20-F Item 12.D p154]

ADR annual depositary services fee at most USD 0.05 per ADS. [20-F p154]

Nov 25 2021 Bank of Canada FXUSDCAD daily average 1.2654. [Valet]

Prepared 2026-11-25 (Vancouver). Currency and units shown on each row.

Peralta factual exhibit: Q3 2026 balance and cash rows

Reconstructed from Novartis Q3 2026 interim physical pp21,25,52; USD millions.

Balance assets Dec2025 110949; Sep2026 117149 USD m. [Q3 p21]

Balance cash Dec2025 11435; Sep2026 8870 USD m. [Q3 p21]

Balance financial debts Dec2025 33537; Sep2026 46349 USD m. [Q3 p21]

Balance leases Dec2025 1920; Sep2026 1961 USD m. [Q3 p21]

Balance common equity Dec2025 46130; Sep2026 37228 USD m. [Q3 p21]

Balance issuer net debt Dec2025 21947; Sep2026 37374 USD m. [Q3 p52]

Peralta factual exhibit: lease financing cash

Reconstructed from Novartis 2025 annual p178 and Q3 2026 interim p25; USD millions.

Annual lease principal 2023 258; 2024 262; 2025 281 USD m. [20-F p178]

9M lease principal 2025 208; 2026 207 USD m. [Q3 p25]